Skip to main content
PBF logo

PBF — Investor Relations & Filings

Ticker · 1760 ISIN · TW0001760007 LEI · 54930078VUU2LBPR2729 TW Manufacturing
Open in API
Filings indexed 1,562 across all filing types
Latest filing 2023-11-09 Regulatory Filings
Country TW Taiwan
Listing TW 1760

About PBF

http://www.pbf.com.tw

Panion & BF Biotech Inc. is a biotechnology company focused on pharmaceutical research, development, and manufacturing. Founded in 1976, the firm operates across several core sectors, including new drug innovation, medical aesthetics, and nutritional supplements. It is recognized for its "Total Aging Management" strategy, which addresses the health needs of an aging population through a diverse product portfolio. Key offerings include treatments for chronic kidney disease, specifically phosphate binders, as well as dermatological drugs, hair care solutions, and rapid diagnostic technologies. The company integrates clinical-grade pharmaceutical standards into its consumer health and aesthetic products, serving markets in chronic disease care and preventative wellness.

Recent filings

Filing Released Lang Actions
112年10月營業收入
Regulatory Filings Classification · 90% confidence The document is a revenue summary report from a listed company, showing monthly and cumulative net operating revenue figures with percentage changes compared to the previous year. It includes notes on accounting standards (IFRS) and reporting practices. The document length is short (777 characters) and it primarily provides summarized financial data without detailed financial statements or management discussion. It does not appear to be a full annual or interim report, nor an earnings release since it lacks key highlights or narrative. It is a regulatory disclosure of financial data, typical of a general regulatory announcement. Therefore, the best fitting category is Regulatory Filings (RNS).
2023-11-09 Chinese
112年10月內部人持股異動(事後)
Director's Dealing Classification · 95% confidence The document consists of detailed tables listing shareholdings and changes in share ownership by insiders, including directors, managers, and their related parties. It includes data on shares held, increases, decreases, and trust shares. The content is focused on insider shareholding disclosures rather than financial results, management changes, or other report types. This matches the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades). The document length is sufficient and contains substantive data on insider shareholdings, not just an announcement or summary. Therefore, the appropriate classification is DIRS.
2023-11-07 Chinese
112年10月董事會成員及持股
Director's Dealing Classification · 95% confidence The document contains detailed tables listing shareholdings and pledged shares of company insiders, including directors, supervisors, and senior management. It provides specific data on share counts, pledged shares, and related parties' holdings. The content focuses on insider shareholdings and changes, which aligns with reporting of personal share transactions or holdings by company directors and executives. There is no indication of financial results, meeting materials, or regulatory announcements unrelated to insider holdings. The document length is 3187 characters, which is relatively short but contains detailed insider shareholding data, not just an announcement or certification. Therefore, the document fits best under the category of Director's Dealing (DIRS).
2023-11-07 Chinese
本公司腎臟新藥拿百磷 (Nephoxil)泰國授權夥伴DKSH (Thailand) Limited 取得NDA新藥進口上市許可
Regulatory Filings Classification · 95% confidence The document is a short announcement from a listed company (寶齡富錦生技股份有限公司) regarding the approval of a new drug (Nephoxil) by the Thai FDA for import and marketing. It includes details about the drug, its intended use, market conditions, and a cautionary note to investors. The document length is only 1291 characters, which is quite short and does not contain any financial statements, detailed financial data, or comprehensive report content. It is an announcement of a significant corporate event related to product approval and market impact, not a financial report or management discussion. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is also not a regulatory certification or officer attestation. The best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2023-10-13 Chinese
112年9月背書保證與資金貸與
Regulatory Filings Classification · 95% confidence The document is a financial disclosure from a listed company providing details about fund loans and endorsement guarantees for the current and previous month, including limits and balances. It is a short report (622 characters) focused on specific financial data related to capital lending and guarantees, without any narrative, management discussion, or comprehensive financial statements. It does not present a full annual or interim report, nor is it an announcement of a report publication. The content fits best as a Regulatory Filing (RNS) because it is a regulatory disclosure of financial information that does not fit into other specific categories like Annual Report, Interim Report, or Capital/Financing Update.
2023-10-11 Chinese
112年9月營業收入
Fund Information / Factsheet Classification · 90% confidence The document is a summarized revenue report from a listed company, showing monthly and cumulative net operating revenue figures with percentage changes compared to the previous year. It includes notes on accounting standards and reporting practices but does not contain comprehensive financial statements or detailed analysis. The document length is short (779 characters) and appears to be a brief financial data summary rather than a full report. It does not announce the publication of a report but provides actual financial figures. Given the nature of the content as a brief summary of key financial facts, it fits best into the Fund Information / Factsheet (FS) category, which covers brief summaries of key company financials and market info.
2023-10-11 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.